<DOC>
	<DOC>NCT02698124</DOC>
	<brief_summary>Prospective multicenter, open-lab el, observational, single arm study of decitabine. Subjects will be elderly patients with newly diagnosed, treatment-naïve AML who are unfit to receive and not candidate for intensive induction chemotherapy (iIC)</brief_summary>
	<brief_title>Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1. Newly diagnosed and therapynaïve AML (bone marrow or peripheral blood blast counts ≥20%) 2. 65 years of age or older 3. Taking informed consent with signature and date 4. Not eligible for iIC based on either: i) ≥75 years of age ii) comorbidity iii) secondary AML iv) poor performance (ECOG ≥2) v) Poorrisk by NCCN Guideline version 1.2015 vi) subject's choice (refusal for iIC) investigator's judgement incompatible with iIC 1. Candidate for iIC at the time of enrollment 2. Promyelocytic leukemia, or AML with t(15;17) or PML/RARα rearrangement 3. AML with t(9;22) or BCR/ABL rearrangement 4. Leukemia central nervous system involvement 5. Extramedullary myeloid sarcoma without bone marrow involvement 6. Prior treatment with decitabine or azacitidine of any cause 7. Any leukemiaspecific therapy, except for hydroxyurea for reducing leukemic cells prior decitabine 8. Second malignancy currently requiring active therapy except breast or prostate cancer stable on or responding to endocrine therapy, or curatively resected nonmelanoma skin cancer or intraepithelial cancer 9. Premenopausal woman 10. Severe active infection 11. Uncontrolled bleeding Hypersensitivity to decitabine</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>